https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=PHASEBIO_PHARMACEUTICALS_INCPHASEBIO PHARMACEUTICALS INC - Revizia istoricului2026-05-18T15:08:54ZIstoricul versiunilor pentru această pagină din wikiMediaWiki 1.39.2https://wiki.tradeville.ro/index.php?title=PHASEBIO_PHARMACEUTICALS_INC&diff=435695&oldid=prevAdmin: Pagină nouă: Pagina dedicata companiei PHASEBIO PHARMACEUTICALS INC listata cu simbolul US.PHAS ==Descriere companie== PhaseBio Pharmaceuticals, Inc. (https://phasebio.com/) is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for cardiopulmonary diseases. The Company’s lead product candidate, bentracimab (PB2452) is a reversal agent for the antiplatelet drug ticagrelor, which the Company is developing for the rever...2024-09-18T18:21:17Z<p>Pagină nouă: Pagina dedicata companiei PHASEBIO PHARMACEUTICALS INC listata cu simbolul US.PHAS ==Descriere companie== PhaseBio Pharmaceuticals, Inc. (https://phasebio.com/) is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for cardiopulmonary diseases. The Company’s lead product candidate, bentracimab (PB2452) is a reversal agent for the antiplatelet drug ticagrelor, which the Company is developing for the rever...</p>
<p><b>Pagină nouă</b></p><div>Pagina dedicata companiei PHASEBIO PHARMACEUTICALS INC listata cu simbolul US.PHAS<br />
<br />
==Descriere companie==<br />
PhaseBio Pharmaceuticals, Inc. (https://phasebio.com/) is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for cardiopulmonary diseases. The Company’s lead product candidate, bentracimab (PB2452) is a reversal agent for the antiplatelet drug ticagrelor, which the Company is developing for the reversal of the antiplatelet effects of ticagrelor in patients with uncontrolled major or life-threatening bleeding or requiring urgent surgery or an invasive procedure. The Company’s second product candidate, pemziviptadil (PB1046) is in Phase II development for the treatment of pulmonary arterial hypertension (PAH). Pemziviptadil utilizes the Company’s half-life extending elastin-like polypeptide technology, which also serves as an engine for the Company’s preclinical pipeline. The Company is also developing its preclinical product candidate, PB6440 for treatment-resistant hypertension.<br />
<br />
==Grafic actiuni companie==<br />
<iframe key="tradeville" path="graficSimbol/US.PHAS" /><br />
<br />
==Ultimele stiri despre PHASEBIO PHARMACEUTICALS INC (US.PHAS)==<br />
<dynamicpagelist><br />
category=US.PHAS<br />
count=10<br />
order=descending<br />
addfirstcategorydate=false<br />
</dynamicpagelist><br />
<br />
[[Categorie:US.PHAS]][[Categorie:Stiri despre companii]]</div>Admin